Bluejay Diagnostics announces 1-for-20 reverse stock split to meet Nasdaq minimum bid price, effective July 24, 2023

Bluejay Diagnostics, Inc.

Reverse split ratio 1-for-20; authorized shares reduced from 100M to 7.5M; outstanding shares from ~20.5M to ~1.02M.
Effective 12:01 a.m. ET July 24, 2023; shares trade post-split on Nasdaq under same symbol BJDX with new CUSIP 095633301.
Split ensures compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing.
No fractional shares issued; cash payment in lieu based on ten-day average closing price.
Outstanding warrants and equity awards adjusted proportionally.

item 3.03 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bluejay Diagnostics, Inc.: Amended certificate of incorporation to implement a 1-for-20 reverse stock split and reduce authorized shares from 100,000,000 to 7,500,000 (effective 2023-07-24).

Change: charter amendment
Effective: 2023-07-24

Exact text from the filing

At the Annual Meeting of Stockholders of Bluejay Diagnostics, Inc. (the “Company”) held on June 14, 2023 (the “Annual Meeting”), the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to implement a reverse stock split of the Company’s common stock, par value $0.0001 per share, with the ratio to be determined by the Board of Directors (the “Board”) of the Company, at ratios of 1-for-5, 1-for-10, 1-for-20 or 1-for-25, respectively, and reduce the number of authorized shares of Common Stock under the Charter from 100,000,000 shares to 30,000,000, 15,000,000, 7,500,000 and 6,000,000 respectively. Thereafter, on July 21, 2023, the Company filed a certificate of amendment to its Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-20 reverse split of its common stock (the “Reverse Stock Split”) and to reduce the number of authorized shares of com

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-058659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.